Literature DB >> 28579804

Expression of urinary miRNAs targeting NLRs inflammasomes in bladder cancer.

Ettore Mearini1, Giulia Poli2, Giovanni Cochetti1, Andrea Boni1, Maria Giulia Egidi1, Stefano Brancorsini2.   

Abstract

AIM OF THE STUDY: Inflammasome, a large complex of NOD-like receptors (NLRs), drives tumor growth and progression. The present study aimed at exploring the alteration in expression of urinary inflammasome-related microRNAs (miRNAs) in bladder cancer (BC). Our previous report demonstrated the up-regulation of NLRs genes (NLRP3, NLRP4, NLRP9 and NAIP) in urine sediments of patients harboring BC. The expression levels of miRNAs targeting these NLRs (miR-146a-5p, miR-106a-5p, miR-17-5p, miR-223-3p, miR-141-3p, miR-19a-3p, miR-145-5p, miR-185-5p) were assayed in the same patient cohort.
MATERIALS AND METHODS: Forty-six subjects affected by BC, 28 healthy controls (CTR0) and 31 subjects with histologically confirmed bladder inflammation (CTR1) were recruited. Total RNA was extracted from urine sediment and resulting cDNA was used for amplification by real-time polymerase chain reaction. MiRNA expression levels were evaluated and compared among selected groups. Patients were further stratified according to tumor stage, grade and risk of recurrence and progression. Moreover, non-muscle invasive low-grade and high-grade (HG) BC patients were compared.
RESULTS: MiR 141-3p and miR-19a-3p expression decreased in CTR1 with respect to both BC and CTR0. In contrast, miR-146a-5p was up-regulated in BC compared with CTR0. MiR106a-5p, miR17-5p and miR19a-5p were significantly up-regulated in HG, high-risk (HR) and non-muscle invasive HG BC patients, while miR-185-5p was significantly higher in muscle invasive tumors, according to T stage stratification.
CONCLUSION: The increased expression of miRNAs targeting NLRs in HG and HR BC patients is in accordance with the decrease in NLR mRNAs observed in our previous report. These data corroborate the direct role of NLR genes and respective regulatory miRNAs in BC making these inflammasome-related molecules a reliable non-invasive tool for BC diagnosis.

Entities:  

Keywords:  NOD-like receptors; bladder cancer; inflammasome; inflammation; miRNA; urine sediment

Year:  2017        PMID: 28579804      PMCID: PMC5449108          DOI: 10.2147/OTT.S132680

Source DB:  PubMed          Journal:  Onco Targets Ther        ISSN: 1178-6930            Impact factor:   4.147


  43 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  Mechanism of NLRP3 inflammasome activation.

Authors:  Fayyaz S Sutterwala; Stefanie Haasken; Suzanne L Cassel
Journal:  Ann N Y Acad Sci       Date:  2014-05-19       Impact factor: 5.691

Review 3.  Inflammasomes in carcinogenesis and anticancer immune responses.

Authors:  Laurence Zitvogel; Oliver Kepp; Lorenzo Galluzzi; Guido Kroemer
Journal:  Nat Immunol       Date:  2012-03-18       Impact factor: 25.606

4.  MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer.

Authors:  Mattia Boeri; Carla Verri; Davide Conte; Luca Roz; Piergiorgio Modena; Federica Facchinetti; Elisa Calabrò; Carlo M Croce; Ugo Pastorino; Gabriella Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

5.  The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis.

Authors:  Hailong Li; Shoupin Xie; Min Liu; Zhaofeng Chen; Xiaojun Liu; Li Wang; Dayan Li; Yongning Zhou
Journal:  Int J Oncol       Date:  2014-05-06       Impact factor: 5.650

6.  Expression of inflammasome-related genes in bladder cancer and their association with cytokeratin 20 messenger RNA.

Authors:  Giulia Poli; Stefano Brancorsini; Giovanni Cochetti; Francesco Barillaro; Maria Giulia Egidi; Ettore Mearini
Journal:  Urol Oncol       Date:  2015-08-15       Impact factor: 3.498

7.  Circulating microRNAs in plasma of patients with gastric cancers.

Authors:  M Tsujiura; D Ichikawa; S Komatsu; A Shiozaki; H Takeshita; T Kosuga; H Konishi; R Morimura; K Deguchi; H Fujiwara; K Okamoto; E Otsuji
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

8.  Downregulation of microRNA-1 and microRNA-145 contributes synergistically to the development of colon cancer.

Authors:  Xuehu Xu; Xiaobing Wu; Qingping Jiang; Yan Sun; Haibo Liu; Rong Chen; Shangbiao Wu
Journal:  Int J Mol Med       Date:  2015-10-09       Impact factor: 4.101

9.  Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.

Authors:  J H Huh; T H Kim; K Kim; J-A Song; Y J Jung; J-Y Jeong; M J Lee; Y K Kim; D H Lee; H J An
Journal:  Br J Cancer       Date:  2013-06-27       Impact factor: 7.640

10.  MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer.

Authors:  Yongbao Wei; Jinrui Yang; Lu Yi; Yinhuai Wang; Zhitao Dong; Ziting Liu; Shifeng Ou-yang; Hongtao Wu; Zhaohui Zhong; Zhuo Yin; Keqin Zhou; Yunliang Gao; Bin Yan; Zhao Wang
Journal:  Sci Rep       Date:  2014-12-18       Impact factor: 4.379

View more
  20 in total

Review 1.  MicroRNAs: Key Players in Bladder Cancer.

Authors:  Qi Li; Helei Wang; Hourong Peng; Qiuping Huang; Ting Huyan; Qingsheng Huang; Hui Yang; Junling Shi
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

2.  Bladder mesenchymal stromal cell-derived exosomal miRNA-217 modulates bladder cancer cell survival through Hippo-YAP pathway.

Authors:  Zhong-Ming Huang; Hai Wang; Zhi-Gang Ji
Journal:  Inflamm Res       Date:  2021-08-14       Impact factor: 4.575

3.  MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1.

Authors:  Xiaoming Yang; Lei Shi; Chengzhi Yi; Yang Yang; Liansheng Chang; Dongkui Song
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

4.  Exosomes in bladder cancer: novel biomarkers and targets.

Authors:  Hao Geng; Qingchen Zhou; Wenhao Guo; Ling Lu; Liangkuan Bi; Yi Wang; Jie Min; Dexin Yu; Zhaofeng Liang
Journal:  J Zhejiang Univ Sci B       Date:  2021-05-15       Impact factor: 3.066

Review 5.  Role of miRNA-19a in Cancer Diagnosis and Poor Prognosis.

Authors:  Alessio Ardizzone; Giovanna Calabrese; Michela Campolo; Alessia Filippone; Dario Giuffrida; Francesca Esposito; Cristina Colarossi; Salvatore Cuzzocrea; Emanuela Esposito; Irene Paterniti
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

6.  Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer.

Authors:  Kati Erdmann; Karsten Salomo; Anna Klimova; Ulrike Heberling; Andrea Lohse-Fischer; Romy Fuehrer; Christian Thomas; Ingo Roeder; Michael Froehner; Manfred P Wirth; Susanne Fuessel
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

7.  Prognostic Biomarker-Based Identification of Drugs for Managing the Treatment of Endometrial Cancer.

Authors:  Dilraj Kaur; Chakit Arora; Gajendra Pal Singh Raghava
Journal:  Mol Diagn Ther       Date:  2021-06-22       Impact factor: 4.074

8.  Prognostic value of preoperative inflammation-based predictors in patients with bladder carcinoma after radical cystectomy.

Authors:  Huiming Gui; Yutong Song; Yongsheng Yin; Hanzhang Wang; Ronald Rodriguez; Zhiping Wang
Journal:  Open Med (Wars)       Date:  2021-05-21

9.  An integrated analysis of key microRNAs, regulatory pathways and clinical relevance in bladder cancer.

Authors:  Dongyang Li; Xuanyu Hao; Yongsheng Song
Journal:  Onco Targets Ther       Date:  2018-05-24       Impact factor: 4.147

10.  MicroRNA-939 Directly Targets HDGF to Inhibit the Aggressiveness of Prostate Cancer via Deactivation of the WNT/β-Catenin Pathway.

Authors:  Jie Situ; Hao Zhang; Zi Jin; Ke Li; Yunhua Mao; Wentao Huang
Journal:  Onco Targets Ther       Date:  2020-05-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.